68Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients.

Sanli Y., Sanli O., Simsek D., Subramaniam R. M.

Nuclear medicine communications, vol.39, no.10, pp.871-880, 2018 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 39 Issue: 10
  • Publication Date: 2018
  • Doi Number: 10.1097/mnm.0000000000000888
  • Journal Name: Nuclear medicine communications
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.871-880
  • Keywords: Ga-68-PET, MRI, Ga-68-PSMA PET, CT, high-risk prostate cancer, MEMBRANE ANTIGEN-EXPRESSION, POSITRON-EMISSION-TOMOGRAPHY, ESTRO-SIOG GUIDELINES, RADICAL PROSTATECTOMY, DIAGNOSTIC-ACCURACY, EXTRACAPSULAR EXTENSION, DISEASE RECURRENCE, LYMPH-NODES, WHOLE-BODY, THERAPY
  • Istanbul University Affiliated: Yes

Abstract

Treatment of high-risk prostate cancer (HRPCa) is challenging. Local staging and metastatic evaluation are important for the patient management. Recently, prostate-specific membrane antigen (PSMA)-based imaging modalities such as PSMA PET/CT and PET/MRI have received significant attention for detection of recurrent prostate cancer sites with elevated prostate-specific antigen levels, after therapy. Current evidence suggests that these imaging modalities may also have a role for the management of patients with HRPCa. In this review, we discuss PSMA-based imaging modalities in the management of patients with HRPCa.